Cosyn Precision Medicin

En nog een WordPress site

  • Home
  • Home
  • General public & Patient Organizations
    • Community Advisory Board (CAB)
    • 22q11
    • ID
    • Autism
    • Schizophrenia
    • Data protection
  • Consortium
    • Major accomplishments
    • Summary and results
    • Publications



About COSYN

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders.

COSYN was a unique pan-European project bringing together leading experts from the relevant clinical fields, genomics, stem cell biology, neurobiology, and strong participation of LE Pharma..

COSYN aimed to address the basis of intellectual disabilities (ID), autism, and schizophrenia by studying the genes and pathways involved in this process and by identifying the interactions through which disease develops in normal and in disease conditions. COSYN focused on genes and pathways involved in synaptic function, as early steps of neuropsychiatric disorders are expected to impact synapse function.

COSYN identified better, more appropriate targets for therapy, provided clinicians and LE Pharma a better understanding of the molecular basis of the diseases at hand, and develop a new disease classification and new cellular assays and drug targets.

Mouse genetics

Modeling a model: Mouse genetics, 22q11.2 Deletion Syndrome, and disorders of cortical circuit development >Download pdf

stem cells carrying 22q11.2

Analysis of induced pluripotent stem cells carrying 22q11.2 deletion >Download pdf


managing adults with 22q11.2

Practical guidelines for managing adults with 22q11.2 deletion syndrome. >Download pdf

Copyright © 2023